Trends-in-Medicine


 
Publisher:  Stephen Snyder
  
Writers:  Lynne Peterson
 Marta Weber
 Diana Woods
  
Editors:  Kathleen Snyder
 Betty Teel
 


Trends-in-Medicine has no financial connections with any pharmaceutical or medical device company. The information and opinions expressed have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter.

Copyright©  2007
No articles may be reproduced without written permission of the publisher.

Return Home

April 2007 Issues

Zelnorm Withdrawn from U.S. Market -- Quick Pulse

Summary: On March 30, 2007 , the FDA announced that, at its request, Novartis was voluntarily withdrawing Zelnorm (tegaserod maleate) from the U.S. market. The decision was based on a meta-analysis of 29 trials which found Zelnorm, a treatment for irritable bowel syndrome (IBS) and constipation, is associated with an unacceptably high risk of heart attack, stroke, and angina.
For subscription information contact Stephen Snyder, Publisher
1879 Avenida Dracaena, Jensen Beach, FL, 34957, 772-334-7409, Fax 772-334-0856

Email webmaster about site: mike@bookcase.com